Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
With promise to “eliminate the HIV epidemic,” and “defeat AIDS in America and beyond,” administration raises questions about policies
While plan will target 48 “hot spots” with services, and people at high risks with PrEP, will it change policies that fuel HIV? More details are […]
WHO releases updated drug-resistant TB guidelines, removing toxic injectables from recommended treatments
With the release of a “pre-final text” of updated guidelines for treatment of multidrug- and rifampicin-resistant tuberculosis, the World Health Organization made official substantial changes to […]
A trial to test the safety of, and immune response prompted by, the latest candidate for a vaccine to protect against Zika virus infection has begun […]
Planned Parenthood “Global Gag Rule” report is latest to diverge sharply from State Department assessment that policy does no harm
Drawing on previously published findings and on-the-ground interviews, a report from Planned Parenthood details damage to global health gains, including in closed programs, weakened civil society, […]